WHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital Raise
Whitehawk said it has secured rights from Hangzhou DAC to use the CPT113 linker-payload technology in up to five additional internally developed programs.
More News
INO Stock Edges Up After Hours As Partner Reports Success In Cervical Dysplasia Trial
The study showed that the treatment helped reverse precancerous changes in the cervix and clear the high-risk HPV virus that causes them in many patients.
SoFi CEO Sees 'Big Opportunity' In Premium Subscriptions As Stock Heads For 6th Weekly Dip
Speaking at the J.P. Morgan Annual Global Technology, Media and Communications Conference, SoFi CEO Anthony Noto highlighted the company’s premium SoFi Plus subscription as a “big opportunity.”
EDSA Stock Soars More Than 700% So Far This Year: Wall Street Eyes Further Upside In Run Up To Acute Kidney Injury Data Reveal
According to data from Koyfin, the sole analyst covering EDSA rates it a ‘Buy’ with a $14 price target.
WVE Stock Edges Up After Positive Early Data For Rare Disease Drug
The Cambridge-based biotech said its drug WVE-006 produced promising effects in patients with the most severe form of alpha-1 antitrypsin deficiency.
CLNN Stock Falls After Roth Labels Accelerated Approval For ALS Drug A ‘Long Shot’
Shares of the company rose 8% during regular trading hours but fell after hours following the analyst note.
Why Did BuzzFeed Stock More Than Double And Top After-Hours Gains?
The digital media company said that media mogul Byron Allen’s family office will acquire a majority stake in the company valued at $120 million.
GPRO Gains Premarket Ahead Of Q1 Report: Earnings To Test Turnaround Narrative
The setup appeared mixed, with a ‘bearish’ retail sentiment reading for GPRO on Stocktwits.
LGVN Stock Slips After Hours As FDA Flags Concerns On Rare Heart Defect Trial Design
Though the firm called the meeting ‘constructive’, investors seem more focused on the agency’s reservations about the laromestrocel trial’s design and its potential to support approval.
Celsius Just Posted A Record Quarterly Report — But The Real Surprise May Be Alani Nu
Celsius reported a 138% year-on-year surge in its Q1 revenue to $783 million, blowing past Wall Street estimates of $761 million.
